Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus

Authors


  • The opinions and assertions expressed herein are the private views of the authors. No endorsement by the Food and Drug Administration is intended or should be inferred.

Ancillary